MMI Launches Largest U.S. Clinical Trial for Robotic Microsurgery with First Patient Enrollment
核心洞察
Medical Microinstruments (搜索) (MMI (搜索)) has enrolled the first patient in the PRECISE clinical study, the largest prospective, multi-center trial of its kind in the U.S. focused on robotic-assisted microsurgery.
The postmarket trial will evaluate the Symani Surgical System (搜索)'s performance in free flap reconstruction and lymphatic repair procedures across up to 455 patients at top cancer centers.
The study addresses a critical gap in microsurgical evidence by providing real-world clinical data on robotic microsurgical outcomes in patient populations requiring precision and long-term results.
Medical Microinstruments (搜索) (MMI (搜索)) has achieved a significant milestone in robotic microsurgery by enrolling the first patient in the PRECISE clinical study, marking the launch of the largest prospective, multi-center clinical trial of its kind in the United States. The postmarket trial is designed to evaluate the performance of MMI's Symani Surgical System (搜索) in free flap reconstruction and lymphatic repair procedures.
Study Design and Scope
The PRECISE study will enroll up to 455 patients across top cancer centers throughout the U.S., representing a substantial commitment to generating robust clinical evidence for robotic-assisted microsurgery. The trial features two distinct patient cohorts: free tissue transfer patients who will be followed for 30 days, and lymphatic repair patients who will be monitored for three months.
Key clinical endpoints include anastomosis patency, ischemia time, limb volume reduction, freedom from device-related adverse events, and quality-of-life outcomes. The first patient was successfully enrolled at a nonprofit academic healthcare organization in Los Angeles by a leading physician in the institution's plastic surgery division.
Clinical Significance and Leadership
"The PRECISE study is a milestone for the broader field of reconstructive microsurgery," said Mark Toland, CEO of MMI (搜索). "It reflects MMI's commitment to building the rigorous clinical evidence needed to expand patient access to advanced microsurgical care and validate the long-term value of robotic assistance in complex procedures."
Dr. Bohdan Pomahac, National Principal Investigator and Division Chief of Plastic and Reconstructive Surgery at Yale Surgery (搜索) and Smilow Cancer Hospital (搜索), emphasized the study's importance: "PRECISE fills a critical gap for the microsurgical community by providing real world clinical evidence on robotic microsurgical outcomes in patient populations where precision and long-term results matter the most."
Technology Platform
The Symani Surgical System (搜索) represents a unique position in the surgical robotics market as the only commercially available surgical robot specifically designed for microsurgery. The system combines proprietary wristed microinstruments with tremor-reducing and motion-scaling capabilities, enabling new levels of precision in anatomically delicate, open surgical procedures.
This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery addresses microvascular repair and lymphatic repair. In Europe and APAC regions, it also addresses peripheral nerve repair. The Symani System has received FDA authorization for use in the U.S. and carries CE Mark approval in Europe.
Broader Clinical Initiative
The PRECISE study represents the beginning of a broader clinical initiative to strengthen the evidence base for robotic technology in microsurgical applications. MMI (搜索), founded in 2015 near Pisa, Italy, has positioned itself to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for patients with complex conditions.
The company has secured backing from global investors including Fidelity Management & Research Company (搜索), Andera Partners (搜索), BioStar (搜索), Deerfield Management (搜索), Fountain Healthcare Partners (搜索), Panakès Partners (搜索), RA Capital (搜索), Sambatech (搜索), and Wellington Partners (搜索), demonstrating significant confidence in the technology's potential impact on microsurgical care.